Two University of Kentucky Markey Cancer Center researchers have each received a Research Scholar Grant from the American ...

A landmark £42 million trial aimed at revolutionising prostate cancer screening has officially begun in the UK, with the first eligible men now invited to participate. Health Secretary Wes Streeting ...

Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis—the detection ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that ...

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and ...

A major new all-island radiotherapy clinical trial aimed at reducing the side effects of prostate cancer treatment has ...

A new experimental drug is showing potential in treating prostate cancer and possibly other forms of the disease. A new immunotherapy drug used in a prostate cancer clinical trial is showing early ...

An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, ...

Outcome-weighted metrics (mortality, 5-year survival, MIR) better capture unmet need than incidence alone when assessing ...

Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis – the detection of a cancer that would never have been diagnosed during a patient’s ...